How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group

Andrea Rubboli; Claudio Fresco; Maurizio Paciaroni; Bianca Rocca; Domenico Pecora; Iolanda Enea; Claudio Cuccia; Giuseppe Rocco Salvatore Patti

doi:10.2459/JCM.0000000000001204

How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group

Andrea Rubboli, Claudio Fresco, Maurizio Paciaroni, Bianca Rocca, Domenico Pecora, Iolanda Enea, Claudio Cuccia, Giuseppe Rocco Salvatore Patti

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

To evaluate the current interpretation of the lower doses of direct oral anticoagulants (DOAC) dabigatran, apixaban, edoxaban and rivaroxaban in nonvalvular atrial fibrillation.

Lingua originale	Inglese
Rivista	Journal of Cardiovascular Medicine
Volume	Publish Ahead of Print
DOI	https://doi.org/10.2459/JCM.0000000000001204
Stato di pubblicazione	Pubblicato - 2021

Accesso al documento

10.2459/JCM.0000000000001204

http://hdl.handle.net/11579/126011

Altri file e collegamenti

handle

Cita questo

Rubboli, A., Fresco, C., Paciaroni, M., Rocca, B., Pecora, D., Enea, I., Cuccia, C., & Patti, G. R. S. (2021). How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. Journal of Cardiovascular Medicine, Publish Ahead of Print. https://doi.org/10.2459/JCM.0000000000001204

@article{5daf538aa9e54636bf83f42618dfaa7f,

title = "How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group",

abstract = "To evaluate the current interpretation of the lower doses of direct oral anticoagulants (DOAC) dabigatran, apixaban, edoxaban and rivaroxaban in nonvalvular atrial fibrillation.",

author = "Andrea Rubboli and Claudio Fresco and Maurizio Paciaroni and Bianca Rocca and Domenico Pecora and Iolanda Enea and Claudio Cuccia and Patti, \{Giuseppe Rocco Salvatore\}",

year = "2021",

doi = "10.2459/JCM.0000000000001204",

language = "English",

volume = "Publish Ahead of Print",

journal = "Journal of Cardiovascular Medicine",

issn = "1558-2027",

publisher = "Lippincott Williams and Wilkins",

}

Rubboli, A, Fresco, C, Paciaroni, M, Rocca, B, Pecora, D, Enea, I, Cuccia, C & Patti, GRS 2021, 'How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group', Journal of Cardiovascular Medicine, vol. Publish Ahead of Print. https://doi.org/10.2459/JCM.0000000000001204

How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. / Rubboli, Andrea; Fresco, Claudio; Paciaroni, Maurizio et al.
In: Journal of Cardiovascular Medicine, Vol. Publish Ahead of Print, 2021.

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

TY - JOUR

T1 - How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group

AU - Rubboli, Andrea

AU - Fresco, Claudio

AU - Paciaroni, Maurizio

AU - Rocca, Bianca

AU - Pecora, Domenico

AU - Enea, Iolanda

AU - Cuccia, Claudio

AU - Patti, Giuseppe Rocco Salvatore

PY - 2021

Y1 - 2021

N2 - To evaluate the current interpretation of the lower doses of direct oral anticoagulants (DOAC) dabigatran, apixaban, edoxaban and rivaroxaban in nonvalvular atrial fibrillation.

AB - To evaluate the current interpretation of the lower doses of direct oral anticoagulants (DOAC) dabigatran, apixaban, edoxaban and rivaroxaban in nonvalvular atrial fibrillation.

UR - https://iris.uniupo.it/handle/11579/126011

U2 - 10.2459/JCM.0000000000001204

DO - 10.2459/JCM.0000000000001204

M3 - Article

SN - 1558-2027

VL - Publish Ahead of Print

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

ER -

How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group

Abstract

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo